Chimerix’s (CMRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Chimerix (NASDAQ:CMRX) in a research report released on Tuesday,Benzinga reports. HC Wainwright currently has a $11.00 price target on the biopharmaceutical company’s stock.

Separately, Wedbush reaffirmed an “outperform” rating and set a $6.00 target price on shares of Chimerix in a research report on Tuesday, December 10th.

Chimerix Price Performance

NASDAQ:CMRX opened at $5.17 on Tuesday. The business’s 50-day moving average is $3.72 and its two-hundred day moving average is $1.92. Chimerix has a 12 month low of $0.75 and a 12 month high of $5.53. The firm has a market capitalization of $464.99 million, a PE ratio of -5.50 and a beta of 0.35.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by insiders.

Institutional Trading of Chimerix

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Deerfield Management Company L.P. Series C bought a new stake in Chimerix in the fourth quarter valued at about $13,124,000. Rosalind Advisors Inc. bought a new stake in Chimerix in the fourth quarter valued at about $10,614,000. Millennium Management LLC increased its holdings in Chimerix by 6.8% in the fourth quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock valued at $8,900,000 after buying an additional 161,795 shares during the last quarter. Marshall Wace LLP increased its holdings in Chimerix by 1,318.5% in the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock valued at $7,705,000 after buying an additional 2,057,864 shares during the last quarter. Finally, Boxer Capital Management LLC bought a new stake in Chimerix in the fourth quarter valued at about $7,169,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.